Histone deacetylases 10 as a prognostic biomarker correlates with tumor microenvironment and therapy response in colorectal cancer

Figure 1 Higher histone deacetylases 10 expression in colorectal cancer and was associated with poor prognosis. A: Higher histone deacetylases 10 (HDAC10) expression in normal and tumor tissues in pan-cancer data from the TIMER website; B: HDAC10 expression analysis in paired colorectal cancer (CRC) samples from TCGA-COAD showed high expression in tumor; C: Quantitative real-time polymerase chain reaction (qRT-PCR) analysis from thirty patients tissues indicated HDAC10 upregulated in CRC; D: Representative cases in normal tissues and CRC showed high HDAC10 expression in CRC. Scale bar, 100 μm and 20 μm; E: Quantification of immunohistochemistry (IHC) positive areas in normal and CRC indicated high levels of HDAC10 in CRC; F: Receiver operating characteristic curve based on HDAC10 for predicting 1-, 3- , 5-year overall survival; G: Kaplan-Meier survival analysis of HDAC10 expression in CRC tissue microarray and TCGA-COAD datasets showed patients with expressing higher levels of HDAC10 had poor prognosis. ^aP < 0.001, ^bP < 0.01, ^cP < 0.05 vs the NC group. The statistical power for comparing the rates between NC group and CRC group in qRT-PCR and IHC experiments using PASS software, and the results were 71% and 73%, respectively. CRC: Colorectal cancer; OS: Overall survival; TCGA: The Cancer Genome Atlas; HDAC10: Histone deacetylases 10; AUC: Area under the curve.